POM-V Prescription Required

Rispoval IBR-Marker Live lyophilisate and diluent for suspension for injection for cattle

Active ingredient: Infectious bovine rhinotraceitis virus

Form

Injection

Species

Cattle

Manufacturer

Zoetis UK Limited

VMD MA No.

42058/5115

What it's used for

For active immunisation of cattle against Infectious Bovine Rhinotracheitis (IBR), to reduce virus shedding and clinical signs including, in female cattle,...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Infectious bovine rhinotrace...

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Rispoval IBR-Marker Live lyophilisate and diluent for suspension for injection for cattle — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

For active immunisation of cattle against Infectious Bovine Rhinotracheitis (IBR), to reduce
virus shedding and clinical signs including, in female cattle, abortions associated with
BoHV-1 infection. A reduction of abortion associated with BoHV-1 infections has been
demonstrated during the second trimester of gestation upon challenge 28 days after

Revised: November 2023
AN: 03127/2022Page 2 of 10
vaccination. Vaccinated cattle can be differentiated from field virus infected animals due to
the marker deletion, unless the cattle were previously vaccinated with a conventional
vaccine or infected with field virus.
Onset of immunity: 7 days following a single intranasal administration.
21 days following a single intramuscular administration.
Duration of immunity following vaccination before 3 months of age: after intranasal
vaccination of calves aged 2 weeks or older without maternally derived antibodies,
immunity lasts until at least 3 months of age, when the animals should be revaccinated via
intramuscular injection.
A proportion of young calves may have maternally derived antibodies to BoHV-1, which
may affect the immune response to vaccination. Consequently, the protection afforded by
the vaccine may not be complete until the revaccination at 3 months of age. Duration of
immunity following vaccination at or after 3 months of age: 6 months.
Additional information on protection from abortion afforded by combined
vaccination of Rispoval IBR-Marker Vivum with Rispoval IBR-Marker Inactivatum*:
prevention of abortion has been demonstrated during the third trimester of gestation upon
BoHV-1 challenge applied 86 days after a single dose booster vaccination using Rispoval
IBR-Marker Inactivatum*, which was administered 6 months after a single dose primary
vaccination by the intramuscular route using Rispoval IBR-Marker Vivum.
* Where this veterinary medicinal product is authorised.

None.

Cattle:
Rare
(1 to 10 animals / 10,000 animals
treated):
Nasal discharge
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Injection site swelling
,
Hypersensitivity reaction
1
Slight transient, serous discharge may occur for up to 7 days following intranasal
inoculation.
Transient swelling up to 3 cm which generally subsides within 7 days; when injected
intramuscularly.
Vaccinated animals should be observed for approximately 30 minutes following
immunisation. If such reactions occur, antiallergics should be administered.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product.
Reports should be sent, preferably via a veterinarian, to either the marketing authorisation
holder or the national competent authority via the national reporting system. See the
package leaflet for respective contact details.

The presence of maternal antibodies can influence the efficacy of the vaccination.
Therefore it is recommended to ascertain the immune status of calves before vaccination
is started.
Vaccinate healthy animals only.

Special precautions for use in animals
In some cases, the vaccine virus may be excreted after intranasal administration from
vaccinated animals. After intranasal administration of a 10-fold overdose, the vaccine virus
was detected for up to 9 days after vaccination. In very young calves and in rare cases,
vaccine virus was excreted until day 18 post intramuscular vaccination with a 10-fold
overdose. Exceptional transmission of the virus from intranasally-vaccinated animals to
non-vaccinated in-contact animals may occur due to the nature of the vaccine even though
no verified data available would indicate that spreading of the vaccine virus occurs in a
group of animals.

Revised: November 2023
AN: 03127/2022Page 3 of 10
It is recommended to vaccinate all the cattle in the herd.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.
Other precautions:
Not applicable.

Immunosuppressive substances, i.e. corticosteroids or Bovine Virus Diarrhoea modified
live vaccines, should be avoided in a period of 7 days prior to and after vaccination as this
may impair the development of the immunity.

Revised: November 2023
AN: 03127/2022Page 4 of 10
Interferon sensitive veterinary medicinal products should not be applied intranasally
following 5 days after intranasal vaccination.
No information is available on the safety and efficacy of this vaccine when used with any
other veterinary medicinal product. A decision to use this vaccine before or after any other
veterinary medicinal product therefore needs to be decided on a case by case basis.

Store in a refrigerator (2 °C – 8 °C).
Do not freeze.

Revised: November 2023
AN: 03127/2022Page 9 of 10
Protect from light.

CCID50*
max. 10
7.0
CCID50*
Excipient:
Diluent:
Water for injections
2 ml
For a full list of excipients, see section

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.